Stay updated on Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page
- Check2 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.5%
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check23 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.8%
- Check37 days agoChange DetectedThe page has removed a citation regarding a clinical trial on pembrolizumab and axitinib for advanced renal cell carcinoma, which was previously included.SummaryDifference0.2%
- Check52 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check66 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding the efficacy and safety of pembrolizumab in combination with axitinib for renal cell carcinoma, while adding a new registry identifier and revision number.SummaryDifference22%
Stay in the know with updates to Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.